CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Mar. 22, 2017--
Aptar Pharma’s innovative and patented preservative-free multidose
Ophthalmic Squeeze Dispenser is available for patients in the U.S.
prescription market for the first time with Allergan’s RESTASIS
MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170322006214/en/
Courtesy of Allergan
This approval and launch makes the Aptar Pharma Ophthalmic Squeeze
Dispenser the very first, and only, U.S. FDA-approved multidose delivery
system to handle prescription eye treatment formulations without any
preservatives.
Meeting the needs of patients
Aptar Pharma is working closely with eye care specialist Allergan to
improve patient safety, achieve dosing accuracy and maintain product
integrity.
Dry eye patients use eye drops on a regular basis, and often for the
rest of their lives. It is well-proven that preserved medications may
cause unpleasant and sometimes serious side effects.
FDA approval
The increasing number of patients experiencing eye irritation or
allergic reactions with preserved formulations appreciate the fact that
preservatives can be removed from eye care medications with Aptar
Pharma’s Ophthalmic Squeeze Dispenser system. RESTASIS® and
RESTASIS MULTIDOSE™ are FDA-approved prescription treatments to help
patients suffering from Chronic Dry Eye to make more of their own tears.
Making ophthalmic solutions easier and safer to deliver
Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more
than 10 years of development and experience in the delivery of
preservative-free ophthalmic solutions. Patients and consumers in
Europe, Latin America and Asia have benefited from this technology since
2012 with more than 100 commercial references now available on the
market.
RESTASIS® is not an artificial tear. It is a prescription
medicine that helps increase the eyes' natural ability to produce tears.
“Our Ophthalmic Squeeze Dispenser technology has been a great success
for our customers,” explained Salim Haffar, President, Aptar Pharma.
“The proven and unrivalled microbiological safety, combined with a
precise and reproducible drop ejection allows pharmaceutical customers
worldwide to enter into discussions with regulatory agencies such as the
FDA.” Mr. Haffar also points out the user-friendliness of the system,
“The ergonomic and pocket-size design and the intuitiveness of a
squeezable container with a low actuation force certainly contribute to
the high levels of acceptance among patients and consumers around the
world.”
Staying ahead of the market
Aptar Pharma's Ophthalmic Squeeze Dispenser provides a unique
competitive advantage by addressing the global trend towards
patient-friendly, cost-effective and preservative-free multidose
dispensers.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global
supplier of a broad range of innovative dispensing and sealing solutions
for the beauty, personal care, home care, prescription drug, consumer
health care, injectables, food and beverage markets. AptarGroup is
headquartered in Crystal Lake, Illinois, with manufacturing facilities
in North America, Europe, Asia and South America. For more information,
visit www.aptar.com.
This press release contains forward-looking statements. Words such as
“expects,” “anticipates,” “believes,” “estimates,” “future” and other
similar expressions or future or conditional verbs such as “will,”
“should,” “would” and “could” are intended to identify such
forward-looking statements. Forward-looking statements are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 and are
based on our beliefs as well as assumptions made by and information
currently available to us. Accordingly, our actual results may differ
materially from those expressed or implied in such forward-looking
statements due to known or unknown risks and uncertainties that exist in
our operations and business environment. Additionally, forward-looking
statements include statements that do not relate solely to historical
facts, such as statements which identify uncertainties or trends,
discuss the possible future effects of current known trends or
uncertainties or which indicate that the future effects of known trends
or uncertainties cannot be predicted, guaranteed or assured. For
additional information on these and other risks and uncertainties,
please see our filings with the Securities and Exchange Commission,
including the discussion under “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation
to update any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170322006214/en/
Source: AptarGroup, Inc.
Media Contact:
Carolyn Penot
Aptar
Pharma
+33 1 39 17 20 38
carolyn.penot@aptar.com
or
Investor
Relations Contact:
Matthew DellaMaria
AptarGroup,
Inc.
815 479 5530
matt.dellamaria@aptar.com